{"id":"5-flurouracil","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"15-40","effect":"Mucositis"},{"rate":"10-30","effect":"Diarrhea"},{"rate":"10-25","effect":"Nausea and vomiting"},{"rate":"5-20","effect":"Hand-foot syndrome"},{"rate":"5-15","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-FU is converted intracellularly to active metabolites that inhibit thymidylate synthase, blocking dTMP synthesis and DNA replication. It also incorporates into RNA, disrupting protein synthesis. This dual mechanism makes it effective against rapidly dividing cancer cells.","oneSentence":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:50.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07276399","phase":"PHASE3","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":500},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07265674","phase":"PHASE3","title":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","status":"RECRUITING","sponsor":"J-Pharma Co., Ltd.","startDate":"2026-01","conditions":"Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)","enrollment":480},{"nctId":"NCT05802056","phase":"PHASE1","title":"Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-29","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":15},{"nctId":"NCT06867822","phase":"PHASE1","title":"Trial of ProAgio in Advanced/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT07041749","phase":"NA","title":"Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Warts of Foot","enrollment":60},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT06831981","phase":"NA","title":"Hyperthermia With Chemoradiotherapy in Rectal Cancer","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-09-11","conditions":"Rectal Cancer","enrollment":264},{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT03336216","phase":"PHASE2","title":"A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-18","conditions":"Advanced Pancreatic Cancer","enrollment":205},{"nctId":"NCT06259058","phase":"PHASE1, PHASE2","title":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-04-01","conditions":"Pancreatic Cancer","enrollment":96},{"nctId":"NCT06210360","phase":"PHASE2","title":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-02-01","conditions":"Pancreatic Cancer","enrollment":134},{"nctId":"NCT00601198","phase":"PHASE2","title":"A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":4},{"nctId":"NCT05599971","phase":"NA","title":"Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2023-02-22","conditions":"Plantar Wart","enrollment":45},{"nctId":"NCT02383966","phase":"PHASE3","title":"Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2015-07-31","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":243},{"nctId":"NCT03221400","phase":"PHASE1, PHASE2","title":"PEN-866 in Patients With Advanced Solid Malignancies","status":"UNKNOWN","sponsor":"Tarveda Therapeutics","startDate":"2017-08-29","conditions":"Carcinoma, Endometrial Adenocarcinoma, Neoplasms","enrollment":340},{"nctId":"NCT00515411","phase":"PHASE2","title":"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-10-23","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":111},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT00911170","phase":"PHASE3","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-03","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":847},{"nctId":"NCT03290820","phase":"PHASE2","title":"Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":184},{"nctId":"NCT00193882","phase":"PHASE3","title":"Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-07-07","conditions":"Esophagus Cancer","enrollment":220},{"nctId":"NCT01695772","phase":"PHASE4","title":"A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-16","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT00705874","phase":"PHASE1","title":"Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Progen Pharmaceuticals","startDate":"2006-05","conditions":"Cancer","enrollment":172},{"nctId":"NCT00052962","phase":"PHASE3","title":"Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-01","conditions":"Gastrointestinal Neoplasm","enrollment":30},{"nctId":"NCT01212718","phase":"PHASE2","title":"Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2001-07","conditions":"Colorectal Cancer, Non Resectable Metastasis, Reference Lesion","enrollment":168}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"FEBRILE NEUTROPENIA"},{"count":5,"reaction":"VOMITING"},{"count":3,"reaction":"ACUTE KIDNEY INJURY"},{"count":3,"reaction":"NEUROPATHY PERIPHERAL"},{"count":3,"reaction":"NEUTROPENIA"},{"count":3,"reaction":"PNEUMONIA"},{"count":2,"reaction":"BLOOD PRESSURE INADEQUATELY CONTROLLED"},{"count":2,"reaction":"COLITIS"},{"count":2,"reaction":"DECREASED APPETITE"},{"count":2,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":365,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["5FU"],"phase":"phase_3","status":"active","brandName":"5-Flurouracil","genericName":"5-Flurouracil","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death. Used for Colorectal cancer, Breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}